New drug aims to reverse deadly wasting in cancer patients

NCT ID NCT07112196

First seen Dec 10, 2025 · Last updated May 14, 2026 · Updated 20 times

Summary

This study tests a new drug called visugromab in about 518 people with advanced lung or bowel cancer who are losing weight unintentionally (cachexia). The goal is to see if the drug helps patients gain weight, improve appetite, and move better compared to a placebo. Participants receive the drug or placebo as a drip every 4 weeks at the clinic.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER-ASSOCIATED CACHEXIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cantonal Hospital St. Gallen (Kantonsspital St. Gallen)

    RECRUITING

    Sankt Gallen, 9000, Switzerland

  • Léon Bérard Center (Centre Léon Bérard)

    RECRUITING

    Lyon, 69008, France

  • Mid Florida Hematology and Oncology Centers

    RECRUITING

    Orange City, Florida, 32763, United States

  • Oslo University Hospital

    RECRUITING

    Oslo, 0372, Norway

  • Specialized Hospital for Active Treatment in Oncology

    RECRUITING

    Haskovo, 6300, Bulgaria

  • University Hospital of A Coruña (Hospital Universitario de A Coruña)

    RECRUITING

    A Coruña, 15006, Spain

  • University Hospital of Zurich (Universitätsspital Zürich)

    RECRUITING

    Zurich, 8006, Switzerland

Conditions

Explore the condition pages connected to this study.